Market Cap 899.06M
Revenue (ttm) 15.93M
Net Income (ttm) -199.34M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,251.35%
Debt to Equity Ratio -6.42
Volume 623,622
Avg Vol 386,844
Day's Range N/A - N/A
Shares Out 145.95M
Stochastic %K 1%
Beta 0.71
Analysts Strong Sell
Price Target $15.48

Company Profile

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 3 80 44 75 00
Address:
50 rue de Dijon, Daix, France
BioRich
BioRich Feb. 1 at 6:24 AM
$ALT So those cowardly bashing $GUTS, did you know that they have compelling data for MASH/MASLD related conditions? Oh, and a much faster path to market? Wouldn't it be something if $GUTS makes it to market with multiple indications faster than $ALT completing a Phase 3 trial (if they actually pursue it)? Wouldn't it be something if $SNY was talking about $GUTS when they were talking about potential acquisitions with multiple, differentiated, indications (paraphrased)? I still believe the $GUTS, $IVA, $GPCR trifecta builds $SNY an Obesity/Fibrosis/MASH/WL Retention powerhouse. Can't wait for this story to play out. Cheers! ~The Mayor Confidently Bearish $ALT Confidently Bullish $GUTS Bullish $SNY Confidently Bullish $IVA Confidently Bullish $GPCR
1 · Reply
S_Franconi
S_Franconi Jan. 29 at 3:49 PM
$IVA Added.
0 · Reply
S_Franconi
S_Franconi Jan. 29 at 3:09 PM
$IVA Wall Street Analysts Predict a 200.59% Upside in Inventiva (IVA): Here's What You Should Know https://www.nasdaq.com/articles/wall-street-analysts-predict-20059-upside-inventiva-iva-heres-what-you-should-know
0 · Reply
S_Franconi
S_Franconi Jan. 29 at 2:53 PM
0 · Reply
POPEYE832
POPEYE832 Jan. 28 at 3:47 PM
$IVA The IVA stock has just been added to the Simplify Propel Opportunities ETF. This ETF aims to track biotech companies considered to be undervalued.
0 · Reply
S_Franconi
S_Franconi Jan. 28 at 3:26 PM
0 · Reply
POPEYE832
POPEYE832 Jan. 28 at 10:45 AM
$IVA Barclays initiated coverage of Inventiva (IVA) with an Overweight rating and $18 price target Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, “strong” underlying fundamentals, and less of a focus on drug pricing to act as “significant tailwinds.”
1 · Reply
SuperGreenToday
SuperGreenToday Jan. 23 at 4:42 AM
0 · Reply
S_Franconi
S_Franconi Jan. 21 at 3:43 PM
$IVA I'm all about $IVA.
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 20 at 4:28 PM
$IVA Current Stock Price: $6.13
0 · Reply
Latest News on IVA
Inventiva S.A. (IVA) Presents at 44th Annual J.P.

Jan 15, 2026, 2:16 PM EST - 19 days ago

Inventiva S.A. (IVA) Presents at 44th Annual J.P.


Inventiva reports 2025 Third Quarter Financial Information¹

Nov 21, 2025, 4:00 PM EST - 2 months ago

Inventiva reports 2025 Third Quarter Financial Information¹


Inventiva announces launch of public offering

Nov 12, 2025, 4:25 PM EST - 2 months ago

Inventiva announces launch of public offering


Inventiva Announces the Implementation of a New ATM Program

Oct 14, 2025, 4:00 PM EDT - 4 months ago

Inventiva Announces the Implementation of a New ATM Program


Inventiva S.A. (IVA) Analyst/Investor Day Transcript

Oct 8, 2025, 7:16 PM EDT - 4 months ago

Inventiva S.A. (IVA) Analyst/Investor Day Transcript


Inventiva Appoints Andrew Obenshain as Chief Executive Officer

Oct 1, 2025, 2:30 AM EDT - 4 months ago

Inventiva Appoints Andrew Obenshain as Chief Executive Officer


Inventiva to Host Analyst and Investor Event on October 8, 2025

Sep 24, 2025, 4:00 PM EDT - 4 months ago

Inventiva to Host Analyst and Investor Event on October 8, 2025


Inventiva receives $10 million milestone payment from CTTQ

Jul 7, 2025, 4:00 PM EDT - 7 months ago

Inventiva receives $10 million milestone payment from CTTQ


Inventiva reports 2025 First Quarter Financial Information¹

May 23, 2025, 2:30 AM EDT - 9 months ago

Inventiva reports 2025 First Quarter Financial Information¹


Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 10:50 AM EDT - 11 months ago

Inventiva S.A. (IVA) Q4 2024 Earnings Call Transcript


Inventiva reports 2024 Third Quarter Financial Information¹

Nov 21, 2024, 4:00 PM EST - 1 year ago

Inventiva reports 2024 Third Quarter Financial Information¹


BioRich
BioRich Feb. 1 at 6:24 AM
$ALT So those cowardly bashing $GUTS, did you know that they have compelling data for MASH/MASLD related conditions? Oh, and a much faster path to market? Wouldn't it be something if $GUTS makes it to market with multiple indications faster than $ALT completing a Phase 3 trial (if they actually pursue it)? Wouldn't it be something if $SNY was talking about $GUTS when they were talking about potential acquisitions with multiple, differentiated, indications (paraphrased)? I still believe the $GUTS, $IVA, $GPCR trifecta builds $SNY an Obesity/Fibrosis/MASH/WL Retention powerhouse. Can't wait for this story to play out. Cheers! ~The Mayor Confidently Bearish $ALT Confidently Bullish $GUTS Bullish $SNY Confidently Bullish $IVA Confidently Bullish $GPCR
1 · Reply
S_Franconi
S_Franconi Jan. 29 at 3:49 PM
$IVA Added.
0 · Reply
S_Franconi
S_Franconi Jan. 29 at 3:09 PM
$IVA Wall Street Analysts Predict a 200.59% Upside in Inventiva (IVA): Here's What You Should Know https://www.nasdaq.com/articles/wall-street-analysts-predict-20059-upside-inventiva-iva-heres-what-you-should-know
0 · Reply
S_Franconi
S_Franconi Jan. 29 at 2:53 PM
0 · Reply
POPEYE832
POPEYE832 Jan. 28 at 3:47 PM
$IVA The IVA stock has just been added to the Simplify Propel Opportunities ETF. This ETF aims to track biotech companies considered to be undervalued.
0 · Reply
S_Franconi
S_Franconi Jan. 28 at 3:26 PM
0 · Reply
POPEYE832
POPEYE832 Jan. 28 at 10:45 AM
$IVA Barclays initiated coverage of Inventiva (IVA) with an Overweight rating and $18 price target Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, “strong” underlying fundamentals, and less of a focus on drug pricing to act as “significant tailwinds.”
1 · Reply
SuperGreenToday
SuperGreenToday Jan. 23 at 4:42 AM
0 · Reply
S_Franconi
S_Franconi Jan. 21 at 3:43 PM
$IVA I'm all about $IVA.
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 20 at 4:28 PM
$IVA Current Stock Price: $6.13
0 · Reply
Quantumup
Quantumup Jan. 20 at 3:46 PM
Citizens⬆️the PT on $MDGL to $745 from $527 and reiterated at Market Outperform. $IVA $NVO $VKTX $ALGS ALT AGMT LLY Citizens said in its note: MDGL shares have pulled in to start 2026 (down 14%), which we think is a knee-jerk reaction to the company not getting bought and the ervogastat deal signaling that a near-term buyout is unlikely. Taking a step back, we consider the potential combo candidates as upside to our valuation, but they diversify the IP risk on Rezdiffra and give us more confidence in the longer-term revenue tail. Management is building out its pipeline from a position of strength, with the Rezdiffra launch exceeding expectations with plenty of room to grow, we like the acquisition candidates to date that are good strategic fits with Rezdiffra, and we are looking forward to the MAESTRO-NASH OUTCOMES data in 2027 in F4 cirrhotics, which, in our view, could double Rezdiffra's commercial opportunity (upside to our valuation today).
1 · Reply
FloatTorch_976
FloatTorch_976 Jan. 19 at 4:10 PM
$IVA Tight range, breakout could trigger a fresh upside move
0 · Reply
THE_ORJINAL
THE_ORJINAL Jan. 16 at 3:51 PM
$ALT Watching $IVA. Steady climb as if it's about to be acquired in next few months. Their MASH Ph3 readout isnt until end of 2027. More MASH M&A will be positive for ALT. Pemvi is perfect combo therapy with something like IVA oral small molecule.
2 · Reply
Mibl
Mibl Jan. 16 at 3:21 PM
$IVA great movement here
1 · Reply
POPEYE832
POPEYE832 Jan. 15 at 8:06 PM
$IVA During the Q&A session following their presentation at the JP Morgan 2026 conference held today, someone asked the CEO whether Inventiva planned to become a U.S. company. The CEO’s response: No, we will remain based in France while developing our commercial infrastructure in the United States in the future. We will transition from a French innovation company to an international, transatlantic company, while remaining headquartered in France.
0 · Reply
POPEYE832
POPEYE832 Jan. 15 at 5:12 PM
0 · Reply
BioRich
BioRich Jan. 15 at 3:09 PM
$OCUL I'll jump on the $SNY buying spree rumor. Think they snag $IVA and $GUTS as well. https://stocktwits.com/news-articles/markets/equity/why-did-ocul-stock-jump-13-in-pre-market-today/cmU1KclR47Y Follow/Subscribe for more suggestions and perspective from our growing community. That's how we find these gems and learn. Let's make some (more) money. Cheers! $XBI
0 · Reply
THE_ORJINAL
THE_ORJINAL Jan. 14 at 7:53 PM
$ALT Helpful comp on Ph3 cost is $IVA. They have 1400 total patients for their Ph3 MASH trial (including placebo). In Oct 2024 they raised $350M for NATiV3. In Nov 2025 they raised another $125M for completing NATiV3 and beginning commercialization efforts. They also filed $300M shelf in Oct 2025. Given ALT Ph3 has similar sized biopsy cohort, it could be in $400M+ ballpark to fully fund just the biopsies cohort. AIM-MASH should help defray cost but then NIT cohort will add cost as well. Hope Durso finds a partner soon. https://seekingalpha.com/news/4158102-inventiva-secures-financing-of-up-to-348m-to-advance-the-nativ3-phase-3-mash-study https://seekingalpha.com/news/4520918-inventiva-announces-125m-us-public-offering-of-adss
1 · Reply
POPEYE832
POPEYE832 Jan. 14 at 9:31 AM
$IVA A low-profile Stocktwits board with very few people, a company that’s neither too big nor too small, ignored by the U.S., with no media hype. It reminds me of an ABVX-type scenario, where everyone was left stunned when they saw +500% in the premarket. It now trades at $124, whereas it was worth $5 or $10 at the time.
2 · Reply
POPEYE832
POPEYE832 Jan. 13 at 8:18 PM
$IVA IVA is starting to climb nicely, with Phase 3 results expected in Q2 or Q3 2026. Up 11% on Euronext today, supported by a solid Phase 2 and a Phase 3 with a large sample size. The company will be present at the JPM 2026 conference, is valued at $1 billion on Nasdaq, and it’s starting to smell like a takeover…
0 · Reply
BioRich
BioRich Jan. 12 at 9:10 PM
$ALT Like to share friendly reminders for $ALT Nation every now and again. They sweet to consistently live in a liberal victimhood mindset so sharing truthful reminders is always good. Sent this back in November when there was much discussion about $ALT 48W data and EoP2 meeting. Many were still pumping Biopsies at 48W (yes, the $ALT Pervi's are indeed this dumb). I/we gently reminded y'all that you're in the wrong game. Since then, $ALT is down significantly, $IVA is up significantly (even after it's SP correction for EU trading...don't ask $ALT, you won't understand, it involves numbers and math). Anyway, cheers to $IVA for continued growth. Early cheers to $SNY for your soon to be released acquisition(s). $ALT, you can't get respect if you never do anything to earn it. (Fibrosis Improvement comparison listed in original post below).
0 · Reply
DARKP00L
DARKP00L Jan. 12 at 12:42 PM
$IVA 07:37 on Jan. 12 2026 Leerink Partners Initiates Coverage On Inventiva with Outperform Rating, Announces Price Target of $12 #tradeideas
0 · Reply